Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Admilparant PK/Safety in Healthy Chinese Participants
NCT05805904Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of admilparant in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration at Day 19, Time of maximum observed concentration at Day 19 and 1 more. Started Mar 2023; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT05805904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05805904.